PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) — Curium, a world chief in nuclear medication, introduced right now that in partnership with its unique distributor SYN Innovation Laboratories in Greece, the primary sufferers in Greece have been injected with PYLCLARI® (INN: Piflufolastat (18F) also referred to as (18 F)-DCFPyL, indicated for the detection of prostate-specific membrane antigen (PSMA) constructive lesions with positron emission tomography (PET) in sufferers with prostate most cancers within the following scientific settings:
-
Primary staging of sufferers with high-risk PCa previous to preliminary healing remedy
-
To localize recurrence of PCa in sufferers with a suspected recurrence based mostly on growing serum prostate-specific antigen (PSA) ranges after major remedy with healing intent
Benoit Woessmer, PET Europe CEO at Curium commented: “We are thrilled that patients in Europe are finally able to benefit from PYLCLARI®, and in particular those patients in Greece via our strong partnership with SYN Innovation Laboratories. As a world leader in nuclear medicine, Curium is pleased to be improving the choice of diagnostic tools available to physicians in Greece to diagnose prostate cancer – ultimately for the benefit of prostate cancer patients.”
Savvas Thalasselis, Managing Director, SYN Innovation Laboratories SA commented: “Today’s announcement of the first dose of PYLCLARI® in Greece is an important milestone for the detection of prostate cancer, in particular for the primary staging of patients with high-risk prostate cancer prior to initial curative therapy. Our long-term partnership with Curium has demonstrated our commitment to diagnosing patients with cancer, and we look forward to further supporting Curium with their future pipeline of diagnostic and therapeutic products.”
Today’s announcement follows the choice in July 2023 by the European Commission granting advertising and marketing authorization for PYLCLARI® within the European Union. SYN Innovation Laboratories has been a associate with Curium since 2017, with unique manufacturing and distribution rights for Curium’s wide selection of positron emission tomography merchandise in Greece. SYN Innovation Laboratories will manufacture PYLCLARI® at its amenities in Athens, Greece.
For extra details about PYLCLARI®: www.pylclari.com
About Curium
Curium is a world chief in nuclear medication. We develop, manufacture, and distribute world-class radiopharmaceutical merchandise to assist sufferers across the globe. Our confirmed heritage mixed with a pioneering method are the hallmarks to ship innovation, excellence, and unparalleled service.
With manufacturing amenities throughout Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical options for life-threatening ailments to over 14 million sufferers yearly. The title ‘Curium’ honors the legacy of pioneering radioactive supplies researchers Marie and Pierre Curie, after whom the radioactive ingredient curium was named and emphasizes our concentrate on nuclear medication. To be taught extra, go to www.curiumpharma.com
For extra info:
Ross Bethell, VP, Head of Global Communications
Curium
[email protected]
About SYN Innovation Laboratories:
It relies in Attica, Greece and is importing and advertising and marketing pharmaceutical and radiopharmaceutical merchandise, medical gear, biotechnology and particular dietary merchandise, with the intention of diagnosing and treating sufferers with most cancers or uncommon ailments. By supplying hospitals and diagnostic facilities has a number one position within the diagnostic imaging sector (MRI, CT, Cath Lab, SPECT,PET)
For extra info:
Savvas Thalasselis, Managing Director
SYN Innovation Laboratories SA
Tel: +30-216 9390105
[email protected]
